Precision drugs reshape advanced lung cancer care as resistance and complexity grow
A Lancet Respiratory Medicine review maps biomarker-matched therapies in advanced NSCLC, from EGFR to emerging targets, and the resistance that limits them.
Resumen
This expert narrative review, the second in a Lancet Respiratory Medicine series, summarizes how biomarker-matched drugs are changing advanced non-small-cell lung cancer. It covers established targets (EGFR, ALK, ROS1, KRAS, BRAF, RET, HER2, MET, NTRK) and emerging ones (NRG1 fusions, MTAP loss, SMARCA4 deficiency). The authors report that newer tyrosine kinase inhibitors, bispecific antibodies and antibody-drug conjugates have improved response durability, intracranial disease control and, in some settings, overall survival. Durable benefit is still limited by acquired resistance, tumour heterogeneity, lineage plasticity and off-target escape, which supports repeat biopsy and circulating-tumour DNA profiling. Treatment choice is growing more complex. This summary is based on the abstract only, so trial-level data are not reported here.
Resumen detallado
Lung cancer is a leading cancer killer, and advanced non-small-cell lung cancer (NSCLC) has been one of the clearest successes of precision oncology. Matching a drug to a tumour's molecular driver now improves outcomes in a growing number of defined subgroups.
This is a narrative review, the second in a Lancet Respiratory Medicine series on lung cancer therapeutics. It summarizes recent advances for established alterations (EGFR, ALK, ROS1, KRAS, BRAF, RET, HER2, MET, NTRK) and discusses emerging targets such as NRG1 fusions, MTAP loss and SMARCA4 deficiency.
Per the abstract, newer-generation tyrosine kinase inhibitors, bispecific antibodies and antibody-drug conjugates have improved response durability and intracranial disease control, and in some settings overall survival. The abstract gives no effect sizes, trial names or patient numbers, so these claims cannot be quantified here.
The authors stress that benefit often fades through acquired resistance, tumour heterogeneity, lineage plasticity and off-target escape. They support repeat tissue biopsy and circulating-tumour DNA profiling to guide later treatment. They also discuss CNS disease, oligoprogression and long-term tolerability, and note that the growing number of monotherapy and combination options makes selection harder. Progress will depend on adaptive strategies and equitable access to comprehensive, timely molecular profiling.
Caveats: this is a review, not new trial data, and it was summarized from the abstract alone. The authors disclose extensive industry relationships. Cancer treatment decisions belong with a specialist oncology team.
Hallazgos clave
- Biomarker-matched therapy now improves outcomes across a growing list of molecularly defined advanced NSCLC subgroups (review-level statement, no data in abstract).
- Newer TKIs, bispecific antibodies and antibody-drug conjugates improved response durability and intracranial control; overall survival improved only in some settings.
- Acquired resistance, tumour heterogeneity, lineage plasticity and off-target escape still limit durable benefit.
- Repeat tissue biopsy and circulating-tumour DNA profiling are supported to guide subsequent treatment.
- Emerging targets include NRG1 fusions, MTAP loss and SMARCA4 deficiency; access to molecular profiling remains uneven.
Metodología
Narrative review (Series paper) in Lancet Respir Med; the abstract does not describe a systematic search, inclusion criteria or quantitative synthesis. Only the abstract was available, so trial-level evidence, sample sizes and effect sizes are not reported here.
Limitaciones del estudio
A narrative review can reflect author selection, and it summarizes others' trials rather than adding new data. The abstract gives no quantitative results, and the authors report extensive industry ties. Its relevance to healthy aging is indirect, as it concerns treatment of established advanced cancer.
¿Te ha gustado este resumen?
Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.
Introduce tu correo electrónico para suscribirte:
